Abstract:Backgrounds: Epidermal growth factor receptor (EGFR) mutation profiles play a vital role in treatment strategy decisions for non–small cell lung cancer (NSCLC). The purpose of this study was to evaluate the predictive efficacy of baseline 18 F-FDG PET/CT-based radiomics analysis for EGFR mutation status, mutation site, and the survival benefit of targeted therapy. Methods: A sum of 313 NSCLC patients with pre-treatment 18 F-FDG PET/CT scans and genetic mutations detection were retrospectively studied. Clinical and PET metabolic parameters were incorporated into independent predictors of determining mutation status and mutation site. The dataset was randomly allocated into the training and the validation sets in a 7:3 ratio. Three-dimensional (3D) radiomics features were extracted from each PET- and CT-volume of interests (VOI) singularly, and then a radiomics signature (RS) associated with EGFR mutation profiles is built by feature selection. Three different prediction models based on support vector machine (SVM), decision tree (DT), and random forest (RF) classifiers were established. Furthermore, nomograms for estimation of overall survival (OS) and progression-free survival (PFS) were established by integrating PET/CT radiomics score (Rad-score), metabolic parameters, and clinical factors. Predictive performance was assessed by the receiver operating characteristic (ROC) analysis and the calibration curve analysis. The decision curve analysis (DCA) was applied to estimate and compare the clinical usefulness of nomograms. Results: Three hundred thirteen NSCLC patients were classified into a training set (n=218) and a validation set (n=95). Multivariate analysis demonstrated that SUVmax and sex were independent indicators of EGFR mutation status and mutation site. Eight CT-derived RS, six PET-derived RS, and two clinical factors were retained to develop integrated models, which exhibited excellent ability to distinguish between EGFR wild type (EGFR-WT), EGFR 19 mutation type (EGFR-19-MT), and EGFR 21 mutation type (EGFR-21-MT). The SVM model outperformed the RF model and the DT model, yielding training area under the curves (AUC) of EGFR-WT, EGFR-19-WT, and EGFR-21-WT, with 0.881, 0.851, and 0.849, respectively, and validation AUCs of 0.926, 0.805 and 0.859, respectively. For prediction of OS, the integrated nomogram is superior to the clinical nomogram and the radiomics nomogram, with C-indexes of 0.80 in the training set and 0.83 in the validation set, respectively. Conclusions: The PET/CT-based radiomics analysis might provide a novel approach to predict EGFR mutation status and mutation site in NSCLC patients and could serve as useful predictors for the patients' survival outcome of targeted therapy in clinical practice.

Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma

CT Delta-Radiomics for Identification of Advanced EGFR-Mutated Lung Adenocarcinoma Sensitive to Therapies Targeting EGFR Pathway

Prediction of Overall Survival and Progression-Free Survival by the 18F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

Prognostic value of combining clinical factors, 18F-FDG PET-based intensity, volumetric features, and deep learning predictor in patients with EGFR-mutated lung adenocarcinoma undergoing targeted therapies: a cross-scanner and temporal validation study

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography-Based Radiomic Features for Prediction of Epidermal Growth Factor Receptor Mutation Status and Prognosis in Patients with Lung Adenocarcinoma

Value of 18F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations

Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer

PET/CT radiomics and machine learning enable non-invasive survival stratification and histologic tumor risk profiling in patients with lung adenocarcinoma

Performance of 18F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients with Non-Small Cell Lung Cancer

Predicting EGFR Mutation Subtypes in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

Prognostic Value of 18F-FDG PET/CT Radiomic Model Based on Primary Tumor in Patients with Non-Small Cell Lung Cancer: A Large Single-Center Cohort Study

Prediction of EGFR-TP53 genes co-mutations in patients with lung adenocarcinoma (LUAD) by 18F-FDG PET/CT radiomics

Subregion-specific 18F-FDG PET-CT radiomics for the pre-treatment prediction of EGFR mutation status in solid lung adenocarcinoma

[Semiquantitative Parameters of 18F-FDG PET/CT, Gene Mutation States of Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase in Prognosis Evaluation of Patients with Lung Adenocarcinoma].

Comprehensive 18F-FDG PET-based Radiomics in Elevating the Pathological Response to Neoadjuvant Immunochemotherapy for Resectable Stage III Non-Small-cell Lung Cancer: A Pilot Study

Radiomics-based Prediction of Survival in Patients with Head and Neck Squamous Cell Carcinoma Based on Pre- and Post-Treatment 18F-PET/CT.

Optimal <SUP>18</SUP>F-FDG PET/CT radiomics model development for predicting EGFR mutation status and prognosis in lung adenocarcinoma: a multicentric study

Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.

Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by <SUP>18</SUP>F-FDG PET/CT Radiomics and Clinicopathological Characteristics

Comprehensive F-18-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study